segmentation

Digital

Synthetic personas turn static, traditional personas into interactive, evidence-backed simulations.

Views & Analysis

Dividing patients into groups based on how they behave towards their condition aids understanding.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.